Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE^®) in the management of hemophilia A

References

• AHCDC, Association of Hemophilia Clinic Directors of Canada website [online] Accessed 11/20/2006. URL: http://www.ahcdc.ca/vWDManagement.html
   Google Scholar
• ArnoldDMJulianJAWalkerIRAssociation of hemophilia Clinic Director of CanadaMortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-upBlood2006108460416551974
   PubMed Web of Science ®Google Scholar
• ArunBKesslerCMColmanRWClowesAWHirshJClinical manifestations and therapy of the hemophiliasHemostasis and thrombosis: basic principles and clinical practice20004Philadelphia, PALippincott, Williams Wilkins
   Google Scholar
• AstermarkJDonfieldSMDiMicheleDMA randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) studyBlood20071095465116990605
   PubMed Web of Science ®Google Scholar
• BatorovaAMartinowitzUContinuous infusion of coagulation factorsHaemophilia200281707712010406
   PubMed Web of Science ®Google Scholar
• BlanchetteVSManco-JohnsonMSantagostinoEOptimizing factor prophylaxis for the haemophilia population: where do we stand?Haemophilia200410Suppl 49710415479380
   PubMed Web of Science ®Google Scholar
• BlanchetteVShapiroALiesnerRADVATE Antihemophilic Factor Plasma/Albumin Free Method (rAHF-PFM): Pharmacokinetics, safety and efficacy in previously treated patients less than 6 years old [poster]The Hemophilia 2006 World Congress2006Vancouver, Canada
   Google Scholar
• BrayGLGompertsEDCourterSA multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study GroupBlood1994832428358167332
   PubMed Web of Science ®Google Scholar
• BrownPBovine spongiform encephalopathy and variant Creutzfeldt-Jakob diseaseBMJ2001322841411290640
   PubMed Web of Science ®Google Scholar
• CDCCenters for Disease Control and Prevention. Report on the Universal Data Collection Program2005719
   Google Scholar
• ChanWWFriedmanHLi-McLeodJImpact of HIV and HCV co-infection on hospitalization and resource use among hemophilia enrollees in a managed care population200545th Annual Interscience Conference on Antimicrobial Agents and ChemotherapyWashington, D.C
   Google Scholar
• CollinsPBlanchetteVFischerKClinical implications of pharmacokinetic variables in the management of patients with severe hemophilia A [poster]Blood2006Orlando, FloridaAmerican Society of Hematology 2006
   Google Scholar
• DiMicheleDInhibitors: resolving diagnostic and therapeutic dilemmasHaemophilia20028280712010424
   PubMed Web of Science ®Google Scholar
• DunnALAbshireTCCurrent issues in prophylactic therapy for persons with hemophiliaActa Haematol20061151627116549891
   PubMed Web of Science ®Google Scholar
• EHC, European Haemophilia Consortium website [online]. Accessed 20 Nove 2006. URL: http://www.wfh.org/2/docs/Resources/EHC/EHC_Fact-sheet_2006.pdf
   Google Scholar
• EPAR Helixate NexGenScientific Discussion [online] Assesed 16 Feb 2007. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Helixatenexgen/301100en6.pdf
   Google Scholar
• EPAR Kogenate BayerScientific Discussion. [online]. Accessed 16 Feb 2007. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Kogenatebayer/101600en6.pdf
   Google Scholar
• ErikssonRKFengeCLindner-OlssonEThe manufacturing process for B-domain deleted recombinant factor VIIISemin Hematol200138243111449332
   PubMed Web of Science ®Google Scholar
• EwensteinBMCollinsPTarantinoMDHemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumine-free methodSemin Hematol2004411, Suppl 211815071785
   PubMedGoogle Scholar
• [FDA] Food and Drug Administration; Center for Biologics Evaluation and Research2006Transmissible Spongiform encephalopathies advisory committee meetingDecember 15, 2006 Issue Summary
   Google Scholar
• FernandezMYuTBjornsonEStability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusionBlood Coagul Fibrinolysis2006171657116575253
   PubMed Web of Science ®Google Scholar
• GruppoRCollinsPShapiroALong-term clinical evaluation of safety, efficacy and immunogenicity of rFVIII Plasma/Albumin Free Method (rAHF-PFM) in previously treated hemophilia A patients – Final Report [poster]The Hemophilia 2006 World Congress2006Vancouver, Canada
   Google Scholar
• HilgartnerMWCurrent treatment of hemophilic arthropathyCurr Opin Pediatr20021446911880733
   PubMed Web of Science ®Google Scholar
• HootsWKHistory of plasma-product safetyTransfus Med Rev20011531011441415
   PubMed Web of Science ®Google Scholar
• HorowitzBPrinceAMHorowitzMSViral safety of solvent-detergent treated blood productsDev Biol Stand199381147618174797
   PubMedGoogle Scholar
• JiangRMonroeTMcRogersRManufacturing challenges in the commercial production of recombinant coagulation factor VIIIHaemophilia20028Suppl 21511966844
   PubMedGoogle Scholar
• KasperCKAledortLMCountsRBA more uniform measurement of factor FVIII inhibitorsThromb Diath Haemorrh197534869721209552
   PubMedGoogle Scholar
• KemptonCLSoucieJMAbshireTCIncidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentratesJourn Thromb Haemost20064257681
   PubMed Web of Science ®Google Scholar
• KeyNInhibitors in congenital coagulation disordersBr J Haematol20041273799115521914
   PubMed Web of Science ®Google Scholar
• KwonJStuartRAddressing the need for improved convenience in hemophilia therapy: A vial reduction analysis in the United StatesThe Hemophilia 2006 World Congress2006Vancouver, Canada
   Google Scholar
• Li-McLeodJFriedmanHTencerTEvaluation of office care for hemophilia patients with HIV and HCV co-infection in a managed care populationHemophilia 2006 World Congress2006Vancouver, Canada
   Google Scholar
• LlewelynCAHewittPEKnightRSPossible transmission of variant Creutzfeldt-Jakob disease by blood transfusionLancet20043634172114962520
   PubMed Web of Science ®Google Scholar
• LusherJMHemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trialsHaematologica20008525 discussion:5–611187864
   PubMedGoogle Scholar
• LuuHSpottsGEwensteinBImmunogenicity profile of ADVATE antihemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM) [poster]The Hemophilia 2006 World Congress2006Vancouver, Canada
   Google Scholar
• Manco-JohnsonMJUpdate on treatment regimens: prophylaxis versus on-demand therapySemin Hematol2003443, Suppl 33914690062
   PubMedGoogle Scholar
• MASAC #177Recommendations for physicians treating patients with hemophilia A and B, von Willebrand Disease, and other congenital bleeding disorders2006
   Google Scholar
• Medical Advisory #406FDA confirms low risk for Creutzfeldt-Jakob disease among persons using plasma-derived factor VIII products licensed in the US2006
   Google Scholar
• NegrierCShapiroABerntopEClinical efficacy and safety evaluation of ADVATE Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF-PFM) during surgical and invasive procedures [poster]The Hemophilia 2006 World Congress2006Vancouver, Canada
   Google Scholar
• NHNew government contracts for recombinant haemophilia products (July 2006)National Hemophilia200615414
   Google Scholar
• Package InsertADVATE® [Antihemophilic factor (recombinant), plasma/albumin-free method] Prescribing InformationBaxter BioScience
   Google Scholar
• Package InsertKogenate FS^® [Antihemophilic Factor (Recombinant), Formulated with Sucrose] Package InsertBayer HealthCare
   Google Scholar
• Package InsertReFacto^® [Antihemophilic Factor (Recombinant)] Prescribing InformationWyeth Pharmaceuticals, Inc.
   Google Scholar
• Package InsertRecombinate® [Antihemophilic Factor (Recombinant]) Prescribing InformationBaxter BioScience
   Google Scholar
• PartiRLeeHYangLStability of plasma/albumin free full-length human factor FVIII (ADVATE rAHF-PFM) after temperature cycling between refrigerated and room temperatureThe Hemophilia 2006 World Congress2006Vancouver, Canada
   Google Scholar
• PartiRSchoppmannALeeHStability of lyophilized and reconstituted plasma/albumin-free recombinant human factor VIII (ADVATE rAHF-PFM)Haemophilia200511492616128893
   PubMed Web of Science ®Google Scholar
• Product MonographADVATE [Antihemophilic Factor (Recombinant), Plasma-Albumin-Free Method]Baxter BioScience2004
   Google Scholar
• RechtMShapiroAInduction of immune tolerance utilizing third generation recombinant factor VIII [ADVATE]: A report of three cases [Poster]2005Sydney, AustraliaISTH
   Google Scholar
• RosendaalFRSmitCVarekampIModern haemophilia treatment: medical improvements and quality of lifeJ Intern Med1990228633402280241
   PubMed Web of Science ®Google Scholar
• ShapiroAAbshireTHernandezFEfficacy and safety of ADVATE rAHF-PFM for perioperative management of hemostasis in previously treated children with hemophilia A [poster]The Hemophilia 2006 World Congress2006Vancouver, Canada
   Google Scholar
• TarantinoMDCollinsPWHayCRClinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia AHaemophilia2004104283715357767
   PubMed Web of Science ®Google Scholar
• UKHCDOUnited Kingdom Haemophilia Centre Doctors’ Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disordersHaemophilia20039123
   Web of Science ®Google Scholar
• ValentinoLAOzaVMBlood safety and the choice of anti-hemophilic factor concentratePediatr Blood Cancer2006472455416724312
   PubMed Web of Science ®Google Scholar
• ValentinoLARechtMDiPaolaJExperience with a third-generation recombinant factor VIII concentrate (ADVATE) for the induction of immune toleranceHemophila 2006 World Congress2006Vancouver, Canada
   Google Scholar
• WhiteGC2ndCourterSBrayGLA multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study GroupThromb Haemost19977766079134639
   PubMed Web of Science ®Google Scholar
• WhiteGCDiMicheleDMertensKUtilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentratesThromb Haemost19998146210102478
   PubMed Web of Science ®Google Scholar
• WightJPaisleySKnightCImmune tolerance induction in patients with haemophilia A with inhibitors: a systematic reviewHaemophilia200394366312828679
   PubMed Web of Science ®Google Scholar